Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt 13.65
IPSEY's Cash to Debt is ranked higher than
83% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. IPSEY: 13.65 )
IPSEY' s 10-Year Cash to Debt Range
Min: 1.43   Max: No Debt
Current: 13.65

Equity to Asset 0.62
IPSEY's Equity to Asset is ranked higher than
71% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IPSEY: 0.62 )
IPSEY' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.66
Current: 0.62

0.28
0.66
Interest Coverage No Debt
IPSEY's Interest Coverage is ranked higher than
94% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. IPSEY: No Debt )
IPSEY' s 10-Year Interest Coverage Range
Min: 15.48   Max: 9999.99
Current: No Debt

15.48
9999.99
F-Score: 9
Z-Score: 5.08
M-Score: -3.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.88
IPSEY's Operating margin (%) is ranked higher than
84% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. IPSEY: 14.88 )
IPSEY' s 10-Year Operating margin (%) Range
Min: 6.53   Max: 21.73
Current: 14.88

6.53
21.73
Net-margin (%) 11.90
IPSEY's Net-margin (%) is ranked higher than
83% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. IPSEY: 11.90 )
IPSEY' s 10-Year Net-margin (%) Range
Min: -2.19   Max: 16.71
Current: 11.9

-2.19
16.71
ROE (%) 16.24
IPSEY's ROE (%) is ranked higher than
91% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. IPSEY: 16.24 )
IPSEY' s 10-Year ROE (%) Range
Min: -2.91   Max: 30
Current: 16.24

-2.91
30
ROA (%) 9.74
IPSEY's ROA (%) is ranked higher than
90% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. IPSEY: 9.74 )
IPSEY' s 10-Year ROA (%) Range
Min: -1.75   Max: 15.26
Current: 9.74

-1.75
15.26
ROC (Joel Greenblatt) (%) 48.67
IPSEY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. IPSEY: 48.67 )
IPSEY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 18.74   Max: 105.8
Current: 48.67

18.74
105.8
Revenue Growth (3Y)(%) 3.60
IPSEY's Revenue Growth (3Y)(%) is ranked higher than
69% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. IPSEY: 3.60 )
IPSEY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.3   Max: 8.8
Current: 3.6

-61.3
8.8
EBITDA Growth (3Y)(%) 9.70
IPSEY's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. IPSEY: 9.70 )
IPSEY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55.7   Max: 9.7
Current: 9.7

-55.7
9.7
EPS Growth (3Y)(%) 14.60
IPSEY's EPS Growth (3Y)(%) is ranked higher than
81% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. IPSEY: 14.60 )
IPSEY' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.5   Max: 14.6
Current: 14.6

-20.5
14.6
» IPSEY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

IPSEY Guru Trades in

IPSEY Guru Trades in

IPSEY Guru Trades in

Q3 2012

IPSEY Guru Trades in Q3 2012

Vanguard Health Care Fund 1,400,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with IPSEY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.10
IPSEY's P/E(ttm) is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. IPSEY: 23.10 )
IPSEY' s 10-Year P/E(ttm) Range
Min: 3.01   Max: 2432.5
Current: 23.1

3.01
2432.5
P/B 3.66
IPSEY's P/B is ranked higher than
71% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. IPSEY: 3.66 )
IPSEY' s 10-Year P/B Range
Min: 1.52   Max: 4.81
Current: 3.66

1.52
4.81
P/S 2.74
IPSEY's P/S is ranked higher than
78% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. IPSEY: 2.74 )
IPSEY' s 10-Year P/S Range
Min: 0.46   Max: 3.99
Current: 2.74

0.46
3.99
PFCF 28.00
IPSEY's PFCF is ranked higher than
90% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPSEY: 28.00 )
IPSEY' s 10-Year PFCF Range
Min: 10.07   Max: 46.82
Current: 28

10.07
46.82
EV-to-EBIT 17.87
IPSEY's EV-to-EBIT is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. IPSEY: 17.87 )
IPSEY' s 10-Year EV-to-EBIT Range
Min: 1   Max: 25.2
Current: 17.87

1
25.2
PEG 16.60
IPSEY's PEG is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPSEY: 16.60 )
IPSEY' s 10-Year PEG Range
Min: 10.99   Max: 16.33
Current: 16.6

10.99
16.33
Shiller P/E 38.28
IPSEY's Shiller P/E is ranked higher than
84% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. IPSEY: 38.28 )
IPSEY' s 10-Year Shiller P/E Range
Min: 6.89   Max: 38.62
Current: 38.28

6.89
38.62
Current Ratio 1.60
IPSEY's Current Ratio is ranked higher than
60% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. IPSEY: 1.60 )
IPSEY' s 10-Year Current Ratio Range
Min: 1.39   Max: 2.32
Current: 1.6

1.39
2.32
Quick Ratio 1.28
IPSEY's Quick Ratio is ranked higher than
62% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. IPSEY: 1.28 )
IPSEY' s 10-Year Quick Ratio Range
Min: 1.1   Max: 2
Current: 1.28

1.1
2

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.35
IPSEY's Dividend Yield is ranked higher than
74% of the 519 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. IPSEY: 1.35 )
IPSEY' s 10-Year Dividend Yield Range
Min: 1.39   Max: 4.36
Current: 1.35

1.39
4.36
Dividend Payout 0.30
IPSEY's Dividend Payout is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPSEY: 0.30 )
IPSEY' s 10-Year Dividend Payout Range
Min: 0.34   Max: 80
Current: 0.3

0.34
80
Dividend growth (3y) 2.20
IPSEY's Dividend growth (3y) is ranked higher than
77% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. IPSEY: 2.20 )
IPSEY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 7.7
Current: 2.2

0
7.7
Yield on cost (5-Year) 1.65
IPSEY's Yield on cost (5-Year) is ranked higher than
75% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. IPSEY: 1.65 )
IPSEY' s 10-Year Yield on cost (5-Year) Range
Min: 1.64   Max: 5.15
Current: 1.65

1.64
5.15
Share Buyback Rate 0.50
IPSEY's Share Buyback Rate is ranked higher than
86% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.30 vs. IPSEY: 0.50 )
IPSEY' s 10-Year Share Buyback Rate Range
Min: 0.5   Max: -187.2
Current: 0.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.88
IPSEY's Price/Tangible Book is ranked higher than
66% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.32 vs. IPSEY: 6.88 )
IPSEY' s 10-Year Price/Tangible Book Range
Min: 3.09   Max: 7.14
Current: 6.88

3.09
7.14
Price/DCF (Projected) 1.82
IPSEY's Price/DCF (Projected) is ranked higher than
89% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. IPSEY: 1.82 )
IPSEY' s 10-Year Price/DCF (Projected) Range
Min: 1.04   Max: 2.32
Current: 1.82

1.04
2.32
Price/Median PS Value 1.34
IPSEY's Price/Median PS Value is ranked higher than
70% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. IPSEY: 1.34 )
IPSEY' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.7
Current: 1.34

0.23
1.7
Price/Graham Number 2.77
IPSEY's Price/Graham Number is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.17 vs. IPSEY: 2.77 )
IPSEY' s 10-Year Price/Graham Number Range
Min: 1.65   Max: 37.31
Current: 2.77

1.65
37.31
Earnings Yield (Greenblatt) 5.60
IPSEY's Earnings Yield (Greenblatt) is ranked higher than
87% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. IPSEY: 5.60 )
IPSEY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4   Max: 103
Current: 5.6

4
103
Forward Rate of Return (Yacktman) 5.02
IPSEY's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. IPSEY: 5.02 )
IPSEY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -45.6   Max: 6.7
Current: 5.02

-45.6
6.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:0MH6.UK, IPNNV.France, IPN.France, I7G.Germany,
Ipsen SA was incorporated on July 28, 1998. It is a biotechnology specialty care company. It produces drugs for uro-oncology, endocrinology, neurology and hematology, and primary care. The Company's segments include Major Western European countries, including France, Italy, Spain, the United Kingdom, and Germany; Rest of Europe, including all other Western and Eastern European countries; North America, mainly including the United States; and Rest of the World, encompassing all countries.
» More Articles for IPSEY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Ipsen’s Somatuline® Depot® is the First Therapy Approved by the FDA in the United States for the... Dec 16 2014
Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of... Dec 16 2014
François Garnier Appointed Executive Vice President, General Counsel of Ipsen Dec 16 2014
Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results... Dec 12 2014
Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA)... Dec 01 2014
Ipsen Announces FDA Acceptance of Filing for Dysport® in the Treatment of Upper Limb Spasticity in... Nov 28 2014
Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARES™, An Enhanced Patient Support Program Nov 24 2014
Ipsen and CNRS Create the "Archi-Pex" Joint Research and Innovation Lab, in Collaboration with the... Nov 20 2014
Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences Nov 18 2014
Ipsen Announces FDA Approval of a New Delivery Device for Somatuline® Depot® (lanreotide)... Nov 06 2014
Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a... Nov 06 2014
Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a... Nov 06 2014
Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a... Nov 06 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology Nov 05 2014
Ipsen: sales in the 3rd quarter and first nine months of 2014 Oct 29 2014
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for... Oct 22 2014
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for... Oct 22 2014
Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate)... Oct 10 2014
Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer Oct 10 2014
Susheel Surpal Steps Down as Executive Vice President, Chief Financial Officer of Ipsen to Pursue... Oct 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK